[go: up one dir, main page]

AR015465A1 - Una formulacion parenteral que comprende 5h-dibenz (b,f)azepin-5-carboxamida y agua o un solvente basado en agua, una forma de dosificacion unitaria y unrecipiente que los comprende y el uso de dicha formulacion para la preparacion de un medicamento - Google Patents

Una formulacion parenteral que comprende 5h-dibenz (b,f)azepin-5-carboxamida y agua o un solvente basado en agua, una forma de dosificacion unitaria y unrecipiente que los comprende y el uso de dicha formulacion para la preparacion de un medicamento

Info

Publication number
AR015465A1
AR015465A1 ARP980105003A ARP980105003A AR015465A1 AR 015465 A1 AR015465 A1 AR 015465A1 AR P980105003 A ARP980105003 A AR P980105003A AR P980105003 A ARP980105003 A AR P980105003A AR 015465 A1 AR015465 A1 AR 015465A1
Authority
AR
Argentina
Prior art keywords
water
formulation
dibenz
azepin
carboxamide
Prior art date
Application number
ARP980105003A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR015465A1 publication Critical patent/AR015465A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Una formulacion parental que comprende una 5H-dibenz(b,f)azepin-5-carboxamida y agua o un solvente basado en agua, donde la formulacion no contiene otrosauxiliares de solubilizacion. La formulacion parenteral es util en el tratamiento de ataques resultantes de por ejemplo, ataque epiléptico. Además se describeuna forma de dosificacion unitaria y un recipiente que comprende una cantidad terapéuticamente efectiva de 5H dibenz(b,f)azepin-5-carboxamida y el uso de dichaformulacion parenteral para lapreparacion de un medicamento
ARP980105003A 1997-10-09 1998-10-07 Una formulacion parenteral que comprende 5h-dibenz (b,f)azepin-5-carboxamida y agua o un solvente basado en agua, una forma de dosificacion unitaria y unrecipiente que los comprende y el uso de dicha formulacion para la preparacion de un medicamento AR015465A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9721497.7A GB9721497D0 (en) 1997-10-09 1997-10-09 Organic compounds

Publications (1)

Publication Number Publication Date
AR015465A1 true AR015465A1 (es) 2001-05-02

Family

ID=10820342

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105003A AR015465A1 (es) 1997-10-09 1998-10-07 Una formulacion parenteral que comprende 5h-dibenz (b,f)azepin-5-carboxamida y agua o un solvente basado en agua, una forma de dosificacion unitaria y unrecipiente que los comprende y el uso de dicha formulacion para la preparacion de un medicamento

Country Status (31)

Country Link
US (2) US6316417B1 (es)
EP (1) EP1033988B1 (es)
JP (2) JP2001519395A (es)
KR (1) KR100760326B1 (es)
CN (1) CN1210032C (es)
AR (1) AR015465A1 (es)
AT (1) ATE257383T1 (es)
AU (1) AU748034B2 (es)
BR (1) BR9812861A (es)
CA (1) CA2304661C (es)
CO (2) CO5090854A1 (es)
CZ (1) CZ298900B6 (es)
DE (1) DE69821024T2 (es)
DK (1) DK1033988T3 (es)
ES (1) ES2214738T3 (es)
GB (1) GB9721497D0 (es)
HU (1) HU226106B1 (es)
ID (1) ID24134A (es)
IL (1) IL135123A0 (es)
MY (1) MY122129A (es)
NO (1) NO327263B1 (es)
NZ (1) NZ503526A (es)
PE (1) PE121998A1 (es)
PL (1) PL192287B1 (es)
PT (1) PT1033988E (es)
RU (1) RU2242231C2 (es)
SK (1) SK286253B6 (es)
TR (1) TR200000870T2 (es)
TW (1) TW584563B (es)
WO (1) WO1999018966A1 (es)
ZA (1) ZA989183B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
CA2624463C (en) * 2005-09-30 2017-02-14 Ovation Pharmaceuticals, Inc. Novel parenteral carbamazepine formulation
WO2007092620A2 (en) * 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
CN101711739B (zh) * 2008-10-08 2012-07-04 中国人民解放军军事医学科学院毒物药物研究所 卡马西平的口服药物组合物
CN105726466A (zh) * 2014-12-10 2016-07-06 辽宁药联制药有限公司 一种奥卡西平注射剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
EP0435826A1 (de) * 1989-12-27 1991-07-03 Ciba-Geigy Ag Intravenöse Lösungen für Status Epilepticus
DE59010072D1 (de) * 1989-12-27 1996-02-29 Ciba Geigy Ag Vorrichtung zum Homogenisieren der inhomogenen Lichtverteilung eines Laserstrahllichtbündels
US5284662A (en) * 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
RU2020972C1 (ru) * 1991-02-07 1994-10-15 Мегдятов Рашид Салехович Способ лечения невралгии тройничного нерва
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine
FR2702148B1 (fr) 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US5466683A (en) * 1994-08-25 1995-11-14 Teva Pharmaceutical Industries Ltd. Water-soluble analogs of carbamazepine

Also Published As

Publication number Publication date
KR20010072533A (ko) 2001-07-31
EP1033988A1 (en) 2000-09-13
HUP0004362A2 (hu) 2001-08-28
MY122129A (en) 2006-03-31
CA2304661A1 (en) 1999-04-22
CN1210032C (zh) 2005-07-13
PL192287B1 (pl) 2006-09-29
NZ503526A (en) 2003-01-31
NO327263B1 (no) 2009-05-25
US6458770B1 (en) 2002-10-01
CO4950520A1 (es) 2000-09-01
GB9721497D0 (en) 1997-12-10
PT1033988E (pt) 2004-05-31
NO20001730L (no) 2000-04-04
WO1999018966A1 (en) 1999-04-22
AU9629898A (en) 1999-05-03
ZA989183B (en) 1999-04-09
JP2005281314A (ja) 2005-10-13
US6316417B1 (en) 2001-11-13
DE69821024T2 (de) 2004-10-28
ID24134A (id) 2000-07-06
HU226106B1 (en) 2008-04-28
SK5052000A3 (en) 2000-12-11
CZ20001279A3 (cs) 2000-07-12
US20020055503A1 (en) 2002-05-09
EP1033988B1 (en) 2004-01-07
JP2001519395A (ja) 2001-10-23
PE121998A1 (es) 1999-12-08
KR100760326B1 (ko) 2007-09-20
CO5090854A1 (es) 2001-10-30
IL135123A0 (en) 2001-05-20
NO20001730D0 (no) 2000-04-04
CA2304661C (en) 2007-12-11
CN1274286A (zh) 2000-11-22
HUP0004362A3 (en) 2006-06-28
BR9812861A (pt) 2000-08-08
HK1031824A1 (en) 2001-06-29
RU2242231C2 (ru) 2004-12-20
PL339446A1 (en) 2000-12-18
ATE257383T1 (de) 2004-01-15
CZ298900B6 (cs) 2008-03-05
ES2214738T3 (es) 2004-09-16
TW584563B (en) 2004-04-21
AU748034B2 (en) 2002-05-30
TR200000870T2 (tr) 2000-10-23
DE69821024D1 (de) 2004-02-12
DK1033988T3 (da) 2004-04-13
SK286253B6 (sk) 2008-06-06

Similar Documents

Publication Publication Date Title
IT1279383B1 (it) Composizione farmaceutica stabilizzata contenente un agente antineoplastico degradabile, relativo solvente stabilizzante avente
NO953769L (no) Pakninger for brettede servietter til engangsbruk og som bevirker utbretting
ES2192338T3 (es) Papel tisu que tiene una mezcla suavizante anhidra sustantiva depositado sobre el.
GEP20022636B (en) 4-[5-Methyl-3-Phenylisoxazol-4-Yl] Benzenesulfonamide, Its Crystal Structure B, Pharmaceutical Composition Containing The Same, Methods For Treatment Or Prophylaxis Of Disorders Caused By Cyclooxygen-2
AR019818A1 (es) Un inmunoconjugado de miostatina.
ES2149264T3 (es) Agente terapeutico para el tratamiento de melanomas.
ATE221059T1 (de) Delta 12,16-isotaxol analoge mit antineoplastischer wirkung und pharmazeutische zusammensetzungen sie enthaltend
AR018026A1 (es) Un material tramado al azar con suavidad mejorada y propiedades de barrera y peso base reducido
MXPA97007996A (es) Preparado para el transporte de sustancias activas a traves de barreras.
AR015465A1 (es) Una formulacion parenteral que comprende 5h-dibenz (b,f)azepin-5-carboxamida y agua o un solvente basado en agua, una forma de dosificacion unitaria y unrecipiente que los comprende y el uso de dicha formulacion para la preparacion de un medicamento
KR910019620A (ko) 15-케토-프로스타글란딘 화합물을 사용한 췌장 질병의 치료
CO5170409A1 (es) Composiciones antitranspirantes
AR242907A1 (es) Dispositivo de doble punta para dosificar y suministrar medicamentos.
ES2071481T3 (es) Prevencion de adherencias sinoviales.
ID19931A (id) Senyawa cincin 7-anggota terfusi tersubstitusi sulfonamida, penggunaannya sebagai obat-obatan, dan pembuatan sediaan farmasi yang mengandung senyawa tersebut
ES2176702T3 (es) Antimicoticos con alta liberacion de sustancia activa.
ID21282A (id) Senyawa-senyawa cincin beranggota-5 terpadu yang disubstitusi sulfonamida, penggunaannya sebagai obat, dan sediaan farmasi yang mengandung senyawa tersebut
ES2098115T3 (es) Esteres de acil l-carnitina y composiciones farmaceuticas que los contienen para tratamiento de shock endotoxico.
AR008154A1 (es) Acido (s)-7-[(4,4'-bipiperidin-1-il)carbonil]-2,3,4,5-tetrahidro-4-metil- -3-oxo-1h-1,4-benzodiazepina-2-acetico, como hidrocloruro del mismo, unacomposicion farmaceutica que lo comprende, el uso del mismo y un procedimiento para su preparacion.
PT1244498E (pt) Combinacao de trimebutina com um analgesico opiode
KR880012231A (ko) 스테로이드의 용도
ITMI931622A0 (it) Procedimento e apparecchiatura di trattamento del liquido di bagnatura in macchine da stampa, particolarmente per macchine da stampa offset.
CO4370014A1 (es) Soluciones inyectables estables de diritromicina
DE69416034D1 (de) Pharmazeutische Zubereitung zur rektalen Verabreichung von pharmakologisch wirksamen Verbindungen
BR9802498A (pt) Estojo para guardar e tansportar materiais e medicamentos de primeiro socorros

Legal Events

Date Code Title Description
FB Suspension of granting procedure